Bradley Maron: A New Era of Human-Centric Cardiovascular Science
Bradley Maron, Editor-in-Chief of Circulation at American Heart Association, shared a post on LinkedIn about a recent article by Joseph C. Wu, published in Circulation, adding:
”Inside the Journal:
Our commitment to basic and translational sciences at Circulation is anchored by Deputy Editor Dr. Joseph C. Wu — a world-recognized powerhouse scientist in cardiovascular disease.
Joe has pioneered key advances in stem cell biology and drug discovery, and is a leading champion of new approach methodologies (NAMs) — creative alternatives to traditional animal models that aim to accelerate promising discoveries toward real clinical application.
Here’s why it matters: animal models have driven real discoveries, but they don’t fully capture the complexity of human cardiovascular disease.
Joe argues the future belongs to human-centric platforms — iPSC-derived heart cells, genome editing, AI, and single-cell multiomics — used together rather than in isolation.
He points to two emerging frontiers: ‘cell villages,’ where cells from thousands of genetically distinct people are studied side by side to capture real human variation, and ‘clinical trial-in-a-dish,’ testing candidate therapies on human cells before they ever reach a patient.
Check out his Perspective article this week in Circulation, where he provides a window into his vision for foundational sciences at the journal.”
Title: Perspectives on the Future of Fundamental Sciences in Cardiovascular Medicine
Author: Joseph C. Wu
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?